

1 Sulaiman, R.S.  
2  
3

4 **A simple optical coherence tomography quantification**  
5 **method for choroidal neovascularization**  
6  
7  
8

9  
10 Rania S. Sulaiman<sup>1,2,3,6</sup>, Judith Quigley<sup>1,2</sup>, Xiaoping Qi<sup>1,2</sup>, Michael N.  
11 O'Hare<sup>1,2,7</sup>, Maria B. Grant<sup>1,2</sup>, Michael E. Boulton<sup>1,2</sup>, Timothy W.  
12 Corson<sup>1,2,3,4,5\*</sup>  
13  
14  
15

16 <sup>1</sup>Eugene and Marilyn Glick Eye Institute, <sup>2</sup>Department of Ophthalmology, <sup>3</sup>Department  
17 of Pharmacology and Toxicology, <sup>4</sup>Department of Biochemistry and Molecular Biology,  
18 Indiana University School of Medicine, Indianapolis, Indiana, <sup>5</sup>Indiana University Melvin  
19 and Bren Simon Cancer Center, Indianapolis, Indiana, <sup>6</sup>Department of Biochemistry,  
20 Faculty of Pharmacy, Cairo University, Cairo, Egypt, <sup>7</sup>School of Biomedical Science,  
21 University of Ulster, Coleraine, Northern Ireland, United Kingdom  
22  
23  
24  
25  
26  
27

28 \*Corresponding author, e-mail; [tcorson@iupui.edu](mailto:tcorson@iupui.edu), Phone: +1-317-274-3305, Fax:  
29 +1-317-274-2277, Address: 1160 West Michigan Street, Indianapolis, IN 46202  
30  
31  
32

33  
34 **Running title:** OCT quantification of CNV volume  
35

36 **Word count:** 2705  
37

38 **Keywords:** Optical coherence tomography, choroidal neovascularization, ophthalmic  
39 imaging, laser-induced CNV, animal models, quantitative analysis  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50

51 This is the author's manuscript of the article published in final edited form as:  
52 Sulaiman, R. S., Quigley, J., Qi, X., O'Hare, M. N., Grant, M. B., Boulton, M. E., & Corson, T. W. (2015). A  
53 Simple Optical Coherence Tomography Quantification Method for Choroidal Neovascularization. *Journal of*  
54 *Ocular Pharmacology and Therapeutics*. <http://dx.doi.org/10.1089/jop.2015.0049>  
55  
56  
57  
58  
59  
60

1 Sulaiman, R.S.  
2

3 **Abstract**  
4

5  
6  
7 **Purpose:** Therapeutic efficacy is routinely assessed by measurement of lesion size  
8 using flatmount retinas and confocal microscopy in the laser-induced choroidal  
9 neovascularization (L-CNV) rodent model. We investigated whether optical coherence  
10 tomography (OCT) quantification, using an ellipsoid volume measurement, was  
11 comparable to standard ex vivo evaluation methods for this model and whether this  
12 approach could be used to monitor treatment-related lesion changes.  
13  
14  
15  
16  
17  
18  
19

20  
21  
22  
23 **Methods:** Bruch's membrane was ruptured by argon laser in the dilated eyes of  
24 C57BL/6J mice, followed by intravitreal injections of anti-VEGF<sub>164</sub> or vehicle, or no  
25 injection. In vivo OCT images were acquired using Micron III or InVivoVue systems at 7,  
26 10, and/or 14 days post-laser and neovascular lesion volume was calculated as an  
27 ellipsoid. Subsequently, lesion volume was compared to that calculated from confocal  
28 Z-stack images of agglutinin stained choroidal flatmounts.  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39

40 **Results:** Ellipsoid volume measurement of orthogonal 2D OCT images obtained from  
41 different imaging systems correlated with ex vivo lesion volumes for L-CNV  
42 (Spearman's  $\rho = 0.82, 0.75, \text{ and } 0.82$  at days 7, 10, and 14, respectively). Ellipsoid  
43 volume calculation allowed temporal monitoring and evaluation of CNV lesions in  
44 response to anti-VEGF treatment.  
45  
46  
47  
48  
49  
50  
51  
52  
53

54 **Conclusions:** Ellipsoid volume measurements allow rapid, quantitative use of OCT for  
55 assessment of CNV lesions in vivo. This novel method can be used with different OCT  
56  
57  
58  
59  
60

Sulaiman, R.S.

imaging systems with sensitivity to distinguish between treatment conditions. It may serve as a useful adjunct to the standard ex vivo confocal quantification, to assess therapeutic efficacy in preclinical models of CNV, and in models of other ocular diseases.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1 Sulaiman, R.S.  
2

3 **Introduction**  
4

5  
6  
7 Choroidal neovascularization (CNV) is the aberrant growth of new blood vessels  
8  
9 originating from the choroid into the subretinal space through a break in Bruch's  
10  
11 membrane.<sup>1</sup> These new vessels can lead to vascular leakage, hemorrhage, formation of  
12  
13 fibrovascular membranes, retinal detachment and eventually, if not treated, to a fibrous  
14  
15 scar.  
16  
17

18  
19  
20  
21 CNV is a major cause of visual loss and is implicated in several neovascular eye  
22  
23 diseases such as the wet (or exudative) form of age-related macular degeneration  
24  
25 (AMD).<sup>2</sup> Wet AMD is responsible for about 90% of AMD-related blindness in individuals  
26  
27 over the age of 55, with about 200,000 new cases diagnosed every year in the United  
28  
29 States alone.<sup>3,4</sup> Laser-induced CNV (L-CNV) is a frequently used experimental  
30  
31 technique in mice and rats that induces breaks in Bruch's membrane and stimulates  
32  
33 blood vessel growth from the choriocapillaris.<sup>5</sup> The resultant CNV resembles aspects of  
34  
35 exudative AMD and can easily be performed in rodents, producing robust subretinal  
36  
37 vascular lesions within 14 days. L-CNV has become the "gold standard" in preclinical  
38  
39 studies,<sup>6</sup> despite limitations of using rodents.<sup>5</sup> This model has been invaluable for the  
40  
41 evaluation of the effects of drug therapies on CNV lesion progression<sup>7,8</sup>  
42  
43  
44  
45  
46  
47  
48

49  
50 Vascular endothelial growth factor (VEGF) has been recognized as a key proangiogenic  
51  
52 factor in CNV. Targeting the VEGF pathway, using specific antibodies, antibody  
53  
54 fragments, or aptamers, is a standard pharmacotherapeutic approach for wet AMD<sup>9</sup> and  
55  
56 has been previously tested in L-CNV experimental models.<sup>10,11</sup> Several methods for 2-  
57  
58  
59  
60

1 Sulaiman, R.S.

2  
3 dimensional (2D) evaluation of L-CNV lesions have been used including histological  
4 analysis and fluorescein angiography.<sup>12</sup> Measuring L-CNV lesion volume using stained  
5 choroidal flatmounts ex vivo allows 3-dimensional (3D) measurement of lesion size,  
6 which is more informative than measuring lesion area alone and has become widely  
7 accepted as a quantitative method to indicate drug efficacy in ameliorating CNV  
8 lesions.<sup>5, 13, 14</sup>

9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20 Although ex vivo lesion measurements of L-CNV are robust and powerful, in vivo  
21 imaging analysis of lesions would allow longitudinal studies. Optical coherence  
22 tomography (OCT) is a non-invasive, in vivo imaging technique that generates high  
23 resolution, cross sectional images of biological systems.<sup>15</sup> The technique has found  
24 extensive use in ophthalmology<sup>15, 16</sup> providing detailed images for both the anterior and  
25 posterior segments of the eye<sup>17</sup> and has become an essential tool for the clinical  
26 evaluation of ocular pathologies such as wet AMD,<sup>18</sup> retinal tumors,<sup>19-21</sup> and retinal  
27 detachment.<sup>22</sup>

28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41 Paralleling its rise to clinical prominence, OCT has been used preclinically to monitor  
42 disease progression, and OCT images have been shown to be comparable to  
43 histological characteristics in disease models,<sup>23-26</sup> including L-CNV.<sup>12, 27</sup> However, to our  
44 knowledge, 3D quantification of lesions in OCT images has previously used specialized  
45 software that is not readily available or compatible with different systems. Moreover, the  
46 correlation between calculated lesion volume from OCT images and ex vivo choroidal  
47 flatmount 3D quantification has not been shown previously. In this study, we show that  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1 Sulaiman, R.S.

2  
3 simple quantification of lesion volumes from OCT images provides reproducible and  
4  
5 comparable evaluation to the ex vivo analytical methods used in the L-CNV mouse  
6  
7  
8 model.  
9

## 10 11 12 **Methods**

### 13 14 15 **Animals**

16  
17  
18  
19  
20 All animal experiments followed the guidelines of the Association for Research in Vision  
21  
22 and Ophthalmology Statement for the Use of Animals in Ophthalmic and Vision  
23  
24 Research and were approved by the Indiana University School of Medicine Institutional  
25  
26 Animal Care and Use Committee. Wild-type female C57BL/6J mice, 6–8 weeks of age,  
27  
28 were purchased from Jackson Laboratory (Bar Harbor, ME). These mice were  
29  
30 anesthetized by intraperitoneal injections of 17.5 mg/kg ketamine hydrochloride and 2.5  
31  
32 mg/kg xylazine.  
33  
34  
35  
36  
37  
38

### 39 **Laser-Induced model of Choroidal Neovascularization**

40  
41  
42 Laser photocoagulation was performed as previously described.<sup>28, 29</sup> Briefly, eyes were  
43  
44 dilated using 1% tropicamide, then underwent laser treatment using 50  $\mu\text{m}$  spot size, 50  
45  
46 ms duration, and 250 mV pulses of an ophthalmic argon green laser, wavelength 532  
47  
48 nm, coupled to a slit lamp. A coverslip was used to allow viewing of the posterior pole of  
49  
50 the eye. Each eye received 3 laser burns centered around the optic nerve at 12, 3, and  
51  
52 9 o'clock positions. The laser-induced damage to Bruch's membrane was identified by  
53  
54 the appearance of a bubble at the site of laser application. Lesions in which bubbles  
55  
56  
57  
58  
59  
60

1 Sulaiman, R.S.

2  
3 were not observed were excluded from the study. Where indicated, intravitreal injections  
4  
5 of anti-mouse VEGF<sub>164</sub> neutralizing antibody (R&D Systems, Minneapolis, MN) (5  
6  
7 ng/eye) or vehicle (phosphate buffered saline) were given immediately after laser in a  
8  
9 0.5 µL volume using a 33-gauge needle. The needle was kept in place for 1 minute to  
10  
11 prevent the reflux of solution when the needle was removed. Eyes were numbed with  
12  
13 tetracaine solution before the injection, and triple antibiotic ointment was used  
14  
15 immediately after the injection to prevent infection. A masked researcher undertook  
16  
17 imaging and analysis to avoid bias.  
18  
19  
20  
21  
22  
23

## 24 **Optical Coherence Tomography**

25  
26  
27  
28 OCT was performed at the indicated times using the Micron III intraocular imaging  
29  
30 system (Phoenix Research Labs, Pleasanton, CA) or the InVivoVue OCT system  
31  
32 (Bioptigen Inc., Research Triangle Park, Durham, NC). These are the two most  
33  
34 commonly used rodent OCT systems. For the Micron system, imaging was done by a  
35  
36 single experimenter (RSS). Before the procedure, eyes were dilated with 1%  
37  
38 tropicamide solution and lubricated with hypromellose ophthalmic demulcent solution  
39  
40 (Gonak) (Akorn, Lake Forest, IL). Mice were then placed on a custom heated stage that  
41  
42 moves freely to position the mouse eye for imaging. Several horizontal and vertical  
43  
44 images were taken per lesion to allow calculation of CNV lesion volume.  
45  
46  
47  
48

49  
50 For the InVivoVue system, experiments were done separately by a second laboratory,  
51  
52 with imaging conducted by JQ. Pupils of mouse eyes were dilated with 1% atropine and  
53  
54 2.5% phenylephrine hydrochloride. Mice were then anesthetized. One drop of 2.5%  
55  
56 hydroxypropyl methylcellulose was administered to eyes before examination. Three  
57  
58  
59  
60

1 Sulaiman, R.S.

2  
3 lateral images (nasal to temporal) were collected, starting at the meridian crossing  
4  
5 through the center of the optic nerve head (ONH), and the corresponding L-CNV injury  
6  
7 spots were identified by contrasts. Composite fundus images (1.4x1.4 mm,  
8  
9 400x100x1x1) were taken centered on the ONH. Corresponding high resolution B-scan  
10  
11 (1.4x1.4 mm, 400x400x1x1) images were then obtained from swept L-CNV spots.  
12  
13  
14  
15  
16  
17  
18  
19

### 20 **Quantification of Lesions as Ellipsoids**

21  
22  
23 Quantification was performed as in Fig. 1, for images obtained from the Micron system.

24  
25 The widest section of the lesions from perpendicular planes were used to calculate  
26  
27 ellipsoid volume using the formula  $V = \frac{4}{3}\pi abc$  where a, b, and c are the radii of the three  
28  
29 axes of the ellipsoid. The radii were manually drawn and measured using ImageJ  
30  
31 software. The CNV lesion borders were defined from the onset of thickening of the  
32  
33 choroidal layer horizontally to the borders of the hyperreflective lesion vertically. The  
34  
35 lesion borders were defined similarly for images obtained using the InVivoVue system.  
36  
37  
38 In this case, quantitative measures, width (a) and depth (b) of the lesion were  
39  
40 measured from the exported central image in B-scanned compositions. The length (c) of  
41  
42 the lesions was calculated from en face images as the difference in distance between  
43  
44 the beginning and the end of the lesion. Images from both the Micron III and InVivoVue  
45  
46 systems were analyzed by two independent graders (RSS and MNO) for interobserver  
47  
48 comparison. The volumes of the three lesions in each eye were averaged and  
49  
50 considered as an n=1 for statistical analysis.  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



1 Sulaiman, R.S.  
2  
3  
4  
5  
6

### 7 **Choroidal flatmount preparation and ex vivo CNV lesion volume quantification** 8 9

10 Fourteen days post-laser, L-CNV mice were euthanized by carbon dioxide asphyxiation  
11 followed by cervical dislocation. Eyes were enucleated and fixed in 4%  
12 paraformaldehyde (PFA) overnight. The anterior segment and the retina were removed,  
13 and the remaining RPE/choroid/sclera was permeabilized by incubation with 0.3%  
14 Triton X-100 followed by incubation with rhodamine labeled *Ricinus communis*  
15 agglutinin I (Vector Labs, Burlingame, CA), in the dark for 45 minutes, to stain blood  
16 vessels. The staining step was followed by two washes with Tris buffered saline with  
17 0.1% Tween-20 (TBST). Flatmounts of the choroid were prepared and mounted with  
18 Vectashield mounting medium (Vector Labs, Burlingame, CA) and Z-stack images were  
19 taken on an LSM700 confocal microscope (Zeiss, Thornwood, NY, USA). ImageJ  
20 software was used to analyze Z-stack images; the summation of the whole stained area  
21 in each section, multiplied by the distance between sections (3  $\mu\text{m}$ ) was used as an  
22 index for the CNV lesion volume.<sup>28</sup> The volumes of the three lesions in each eye were  
23 averaged and considered as an n=1 for statistical analysis.  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47

### 48 **Statistical analysis** 49 50

51 Statistical analysis was performed with GraphPad Prism 6 software. CNV volume was  
52 compared between treatments using the Mann-Whitney test. The Spearman correlation  
53 coefficient was used to assess the correlation between lesion volumes measured by  
54  
55  
56  
57  
58  
59  
60

1 Sulaiman, R.S.

2  
3 OCT and choroidal flatmounts. P-values  $\leq 0.05$  were considered statistically significant.  
4  
5  
6  
7

## 8 **Results**

### 9 **Ellipsoid quantification in vivo is comparable to ex vivo analysis in L-CNV**

10  
11  
12  
13 Although Z-stack analysis of wholemounds gives robust and reproducible data, we  
14  
15  
16 sought a simple means of evaluating L-CNV lesion volume in vivo. Mice underwent  
17  
18  
19 OCT 14 days post-laser. Comparing volumetric measurements of OCT and agglutinin-  
20  
21  
22 stained wholemound Z-stacks, significant correlation was observed by two independent  
23  
24  
25 graders; grader 1 with  $\rho = 0.79$ ,  $P < 0.01$  and grader 2  $\rho = 0.78$ ,  $P < 0.05$  (Fig. 2). The  
26  
27  
28 intraobserver correlation (based on repeated analysis of the same dataset) was  $\rho = 0.9$ ,  
29  
30  
31  $P < 0.001$ , while the interobserver correlation was  $\rho = 0.73$ ,  $P < 0.05$ .  
32  
33  
34  
35  
36

### 37 **Ellipsoid quantification is sensitive to different treatment conditions**

38  
39 In the L-CNV model, anti-VEGF antibodies have previously been shown to reduce CNV  
40  
41  
42 lesion volume, based on Z-stack image quantification, compared to vehicle treated  
43  
44  
45 controls.<sup>30</sup> We first sought to reproduce this amelioration in the CNV lesion size using  
46  
47  
48 the L-CNV mouse model and to compare the difference between treatment groups  
49  
50  
51 using both confocal microscopy and OCT. Quantification of CNV lesion volume using  
52  
53  
54 the standard Z-stack image method showed the expected significant reduction, about  
55  
56  
57 35%,<sup>31</sup> in lesion volume after anti-VEGF treatment compared to vehicle controls (Fig. 3).  
58  
59  
60

1 Sulaiman, R.S.

2  
3 Interestingly, CNV lesion volume calculated using this method from OCT images  
4  
5 obtained 7 days after laser and injection also demonstrated a significant reduction,  
6  
7 likewise about 35%, after anti-VEGF treatment (Fig. 4). Similar results were obtained  
8  
9 from images after 14 days (Fig. 4). Importantly, OCT volume measurements  
10  
11 significantly correlated with those measured by Z-stack quantification, after 7 days ( $\rho =$   
12  
13 0.82,  $P < 0.01$ ) (Fig. 5A), and after 14 days ( $\rho = 0.82$ ,  $P < 0.01$ ) (Fig. 5B).  
14  
15  
16  
17  
18  
19

### 20 **Ellipsoid quantification is OCT platform-independent**

21  
22 To validate that our ellipsoidal volume measurement technique could be applied to  
23  
24 images from another automated OCT system, we evaluated L-CNV lesions using OCT  
25  
26 images obtained with the InVivoVue system. Laser burns were applied to mouse eyes  
27  
28 and after 10 days, lesions were evaluated by OCT in vivo. Lesion volumes were  
29  
30 calculated by ellipsoid volume equation, and again compared to volumetric  
31  
32 measurements of CNV lesion volumes from agglutinin stained choroidal flatmounts ex  
33  
34 vivo after 14 days. Interestingly, a significant correlation was again observed between  
35  
36 ellipsoid volume calculation and confocal Z-stack images (Fig. 6) ( $\rho = 0.75$ ,  $P < 0.05$ ).  
37  
38 Similar correlation values were obtained by a second grader to account for  
39  
40 interobserver variability (data not shown). Moreover, removing the peak point, which  
41  
42 might be an outlier, did not change the correlation ( $\rho = 0.75$ ,  $P < 0.05$ ).  
43  
44  
45  
46  
47  
48  
49

### 50 **Discussion**

51  
52  
53  
54 OCT imaging represents an essential adjunct in clinical diagnosis and monitoring of  
55  
56 numerous ocular diseases, such as AMD.<sup>20, 32</sup> Evaluation of L-CNV in vivo using OCT  
57  
58  
59  
60

1 Sulaiman, R.S.

2  
3 imaging has been previously studied in different species such as monkeys,<sup>33, 34</sup>  
4  
5 rabbits,<sup>35</sup> and rats.<sup>27, 36, 37</sup> Others have evaluated OCT in the mouse model of L-CNV  
6  
7 used here by comparing OCT imaging to immunostaining and histological analyses.<sup>12,</sup>  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

38, 39 However, in this study, we compared for the first time OCT quantification of L-CNV lesions to the robust and commonly used ex vivo agglutinin stained choroidal wholemount quantification method, which allows volumetric measurements of L-CNV lesions through Z-stack sections.<sup>5, 13</sup> We saw excellent correlation between the two methods using different OCT imaging systems.

Quantification of OCT images usually requires specialized, proprietary software that is not necessarily compatible with multiple imaging systems. In this study, we showed that quantitative OCT analysis by a simple method allowed in vivo evaluation and monitoring of choroidal lesions in the L-CNV model using two of the most commonly used OCT imaging systems. Although we used ImageJ for analysis, the radii measurements needed for ellipsoid volume could be done using any image-editing program.

Quantification of L-CNV lesions, obtained from either Micron or InVivoVue OCT images, using an ellipsoid volume calculation, provides reproducible and comparable results to the standard ex vivo quantification method. Consistently, we observed a significant correlation, by two independent graders, between OCT images obtained at day 7, 10, or 14 post-laser, and Z-stack confocal measurements at day 14. However, due to the difference in scaling of the Micron III and InVivoVue imaging systems; calculated lesion volumes by Micron OCT were uniformly larger than those calculated by confocal microscopy. Tissue shrinkage during fixation may also contribute to this finding.

1 Sulaiman, R.S.

2  
3 Alternatively, since the length of the lesion (dimension *c*) on the InVivoVue was  
4  
5 obtained from en face images directly, not from vertical scans as was done with the  
6  
7 Micron III system, this might induce some differences in the final calculation. Thus,  
8  
9 using the same volumetric measurement system throughout the analysis of an  
10  
11 experiment is important.  
12  
13  
14  
15  
16

17 Our method also applies to OCT imaging to assess pharmacotherapeutic efficacy. Here,  
18  
19 as proof of concept, we used the standard anti-VEGF antibody treatment, versus  
20  
21 vehicle treatment, to ameliorate CNV lesion volume. To our knowledge, this is the first  
22  
23 use of OCT to show therapeutic effect in the murine L-CNV model, although OCT has  
24  
25 been used similarly in macaques.<sup>34</sup> As we show, OCT can be used to monitor drug  
26  
27 response longitudinally in the same animal, reducing animal usage and enabling time-  
28  
29 course comparisons. For instance, we noted that mean L-CNV lesion volumes  
30  
31 decreased from Day 7 to Day 14 (Fig. 4, 5), but the distinction between anti-VEGF and  
32  
33 vehicle treatments remained about 35% as previously shown.<sup>31</sup>  
34  
35  
36  
37  
38  
39

40  
41 OCT analysis is also rapid. Preparation of choroidal flatmounts for the quantification of  
42  
43 L-CNV lesion volume is a technically involved and time-consuming technique, requiring  
44  
45 at least one overnight step and considerable confocal imaging time, as well as  
46  
47 expensive reagents (fluorescent agglutinin in particular).<sup>5</sup> Conversely, acquiring multiple  
48  
49 images on an OCT system takes about 5 –10 minutes per eye followed by 5 minutes for  
50  
51 calculation of the lesion volume. Therefore, our ellipsoid volume quantification method  
52  
53 represents an inexpensive, rapid, yet reliable quantification method for lesions from  
54  
55  
56  
57  
58  
59  
60

1 Sulaiman, R.S.

2  
3 OCT images. Despite that, it is important to mention that OCT quantification is not a  
4  
5 replacement for the Z-stack confocal measurement. However, it might provide an early  
6  
7 prediction of therapeutic effects as well as a second evaluation method for CNV lesion  
8  
9 volume.  
10

11  
12  
13 One limitation of this method is the manual detection of CNV lesion dimensions, which  
14  
15 might introduce bias to treatment conditions. However, this can be avoided when the  
16  
17 experimenter is masked to treatments throughout imaging and analysis, as well as  
18  
19 using at least two independent graders for volumetric analysis. True CNV lesion shape  
20  
21 is likely not a simple ellipsoid; therefore, using a simple ellipsoid volume measurement  
22  
23 may overestimate irregularly shaped lesions.<sup>39</sup> However, following from this, in  
24  
25 experiments comparing CNV-lesion reducing therapies to control conditions it is likely  
26  
27 that our method would be quite conservative (by potentially *overestimating* lesion  
28  
29 volume and thus *underestimating* treatment effects), which might be considered as a  
30  
31 strength. Like any OCT analysis, our method also requires a clear cornea and lens, and  
32  
33 lesions in or near the central retina. This method is also limited to disease models that  
34  
35 involve localized lesions that can be demarcated by OCT, such as L-CNV. However, a  
36  
37 strength of our method is that it can be used to calculate volumes from the L-CNV  
38  
39 murine model using different automated imaging systems, specifically the Micron and  
40  
41 InVivoVue products.  
42  
43  
44  
45  
46  
47  
48  
49  
50

51  
52  
53 This study provides evidence that OCT is a valuable tool to rapidly and quantitatively  
54  
55 evaluate response to drug therapies for choroidal neovascularization using the L-CNV  
56  
57  
58  
59  
60

1 Sulaiman, R.S.

2  
3 mouse model. Our simple ellipsoidal quantification method may also be applied to the  
4  
5 analysis of other focal intraocular lesions and provides rapid analysis for preclinical  
6  
7 testing of possible therapeutic agents.  
8  
9

## 10 11 12 **Acknowledgements**

13  
14  
15 This work was supported by the International Retinal Research Foundation, the Retina  
16  
17 Research Foundation, and an unrestricted grant from Research to Prevent Blindness,  
18  
19 Inc. TWC is supported by NIH KL2TR001106. MEB is supported by R01EY018358.  
20  
21 MBG is supported by R01HL110170-03, R01EY007739-23, R01EY012601-15, and  
22  
23 R01DK090730-04.  
24  
25  
26  
27  
28  
29  
30  
31

## 32 **Author disclosure statement**

33  
34  
35 TWC has received research and travel support from Phoenix Research Labs. No  
36  
37 competing financial interests exist for the other authors.  
38  
39  
40  
41  
42

## 43 **References**

- 44  
45  
46  
47 1. de Jong PT. Age-related macular degeneration. *N Engl J Med.* 2006; 355:1474-  
48 1485.  
49 2. Jager RD, Mieler WF, Miller JW. Age-related macular degeneration. *N Engl J*  
50 *Med.* 2008; 358:2606-2617.  
51 3. Congdon N, O'Colmain B, Klaver CC, et al. Causes and prevalence of visual  
52 impairment among adults in the United States. *Arch Ophthalmol.* 2004; 122:477-  
53 485.  
54 4. Grossniklaus HE, Green WR. Choroidal neovascularization. *Am J Ophthalmol.*  
55 2004; 137:496-503.  
56  
57  
58  
59  
60

Sulaiman, R.S.

5. Lambert V, Lecomte J, Hansen S, et al. Laser-induced choroidal neovascularization model to study age-related macular degeneration in mice. *Nat Protoc.* 2013; 8:2197-2211.
6. Grossniklaus HE, Kang SJ, Berglin L. Animal models of choroidal and retinal neovascularization. *Prog Retin Eye Res.* 2010; 29:500-519.
7. Dobi ET, Puliafito CA, Destro M. A new model of experimental choroidal neovascularization in the rat. *Arch Ophthalmol.* 1989; 107:264-269.
8. Sulaiman RS, Basavarajappa HD, Corson TW. Natural product inhibitors of ocular angiogenesis. *Exp Eye Res.* 2014; 129:161-171.
9. Prasad PS, Schwartz SD, Hubschman JP. Age-related macular degeneration: current and novel therapies. *Maturitas.* 2010; 66:46-50.
10. Saishin Y, Saishin Y, Takahashi K, et al. VEGF-TRAP(R1R2) suppresses choroidal neovascularization and VEGF-induced breakdown of the blood-retinal barrier. *J Cell Physiol.* 2003; 195:241-248.
11. Krzystolik MG, Afshari MA, Adamis AP, et al. Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. *Arch Ophthalmol.* 2002; 120:338-346.
12. Giani A, Thanos A, Roh MI, et al. In vivo evaluation of laser-induced choroidal neovascularization using spectral-domain optical coherence tomography. *Invest Ophthalmol Vis Sci.* 2011; 52:3880-3887.
13. Sengupta N, Caballero S, Mames RN, et al. The role of adult bone marrow-derived stem cells in choroidal neovascularization. *Invest Ophthalmol Vis Sci.* 2003; 44:4908-4913.
14. Sengupta N, Caballero S, Mames RN, et al. Preventing stem cell incorporation into choroidal neovascularization by targeting homing and attachment factors. *Invest Ophthalmol Vis Sci.* 2005; 46:343-348.
15. Huang D, Swanson EA, Lin CP, et al. Optical coherence tomography. *Science.* 1991; 254:1178-1181.
16. Chen TC, Cense B, Pierce MC, et al. Spectral domain optical coherence tomography: ultra-high speed, ultra-high resolution ophthalmic imaging. *Arch Ophthalmol.* 2005; 123:1715-1720.
17. Drexler W, Morgner U, Ghanta RK, et al. Ultrahigh-resolution ophthalmic optical coherence tomography. *Nat Med.* 2001; 7:502-507.
18. Jia Y, Bailey ST, Wilson DJ, et al. Quantitative optical coherence tomography angiography of choroidal neovascularization in age-related macular degeneration. *Ophthalmology.* 2014; 121:1435-1444.
19. Espinoza G, Rosenblatt B, Harbour JW. Optical coherence tomography in the evaluation of retinal changes associated with suspicious choroidal melanocytic tumors. *Am J Ophthalmol.* 2004; 137:90-95.
20. Rootman DB, Gonzalez E, Mallipatna A, et al. Hand-held high-resolution spectral domain optical coherence tomography in retinoblastoma: clinical and morphologic considerations. *Br J Ophthalmol.* 2013; 97:59-65.
21. Shields CL, Pellegrini M, Ferenczy SR, Shields JA. Enhanced depth imaging optical coherence tomography of intraocular tumors: from placid to seasick to rock and rolling topography--the 2013 Francesco Orzalesi Lecture. *Retina.* 2014; 34:1495-1512.



Sulaiman, R.S.

22. Wolfensberger TJ, Gonvers M. Optical coherence tomography in the evaluation of incomplete visual acuity recovery after macula-off retinal detachments. *Graefes Arch Clin Exp Ophthalmol*. 2002; 240:85-89.
23. Fischer MD, Huber G, Beck SC, et al. Noninvasive, in vivo assessment of mouse retinal structure using optical coherence tomography. *PLoS One*. 2009; 4:e7507.
24. Huber G, Beck SC, Grimm C, et al. Spectral domain optical coherence tomography in mouse models of retinal degeneration. *Invest Ophthalmol Vis Sci*. 2009; 50:5888-5895.
25. Corson TW, Samuels BC, Wenzel AA, et al. Multimodality imaging methods for assessing retinoblastoma orthotopic xenograft growth and development. *PLoS One*. 2014; 9:e99036.
26. Wenzel AA, O'Hare MN, Shadmand M, Corson TW. Optical coherence tomography enables imaging of tumor initiation in the TAG-RB mouse model of retinoblastoma. *Mol Vis*. 2015; In press.
27. Fukuchi T, Takahashi K, Shou K, Matsumura M. Optical coherence tomography (OCT) findings in normal retina and laser-induced choroidal neovascularization in rats. *Graefes Arch Clin Exp Ophthalmol*. 2001; 239:41-46.
28. Qi X, Cai J, Ruan Q, et al.  $\gamma$ -Secretase inhibition of murine choroidal neovascularization is associated with reduction of superoxide and proinflammatory cytokines. *Invest Ophthalmol Vis Sci*. 2012; 53:574-585.
29. Sengupta N, Afzal A, Caballero S, et al. Paracrine modulation of CXCR4 by IGF-1 and VEGF: implications for choroidal neovascularization. *Invest Ophthalmol Vis Sci*. 2010; 51:2697-2704.
30. Campa C, Kasman I, Ye W, et al. Effects of an anti-VEGF-A monoclonal antibody on laser-induced choroidal neovascularization in mice: optimizing methods to quantify vascular changes. *Invest Ophthalmol Vis Sci*. 2008; 49:1178-1183.
31. Liu L, Qi X, Chen Z, et al. Targeting the IRE1 $\alpha$ /XBP1 and ATF6 arms of the unfolded protein response enhances VEGF blockade to prevent retinal and choroidal neovascularization. *Am J Pathol*. 2013; 182:1412-1424.
32. Keane PA, Patel PJ, Liakopoulos S, et al. Evaluation of age-related macular degeneration with optical coherence tomography. *Surv Ophthalmol*. 2012; 57:389-414.
33. Wang Q, Lin X, Xiang W, et al. Assessment of laser induction of Bruch's membrane disruption in monkey by spectral-domain optical coherence tomography. *Br J Ophthalmol*. 2015; 99:119-124.
34. Onami H, Nagai N, Machida S, et al. Reduction of laser-induced choroidal neovascularization by intravitreal vasohibin-1 in monkey eyes. *Retina*. 2012; 32:1204-1213.
35. Koinzer S, Saeger M, Hesse C, et al. Correlation with OCT and histology of photocoagulation lesions in patients and rabbits. *Acta Ophthalmol*. 2013; 91:e603-611.
36. Liu T, Hui L, Wang YS, et al. In-vivo investigation of laser-induced choroidal neovascularization in rat using spectral-domain optical coherence tomography (SD-OCT). *Graefes Arch Clin Exp Ophthalmol*. 2013; 251:1293-1301.
37. Jiao J, Mo B, Wei H, Jiang YR. Comparative study of laser-induced choroidal neovascularization in rats by paraffin sections, frozen sections and high-

1 Sulaiman, R.S.

2  
3 resolution optical coherence tomography. *Graefes Arch Clin Exp Ophthalmol.*  
4 2013; 251:301-307.

5  
6 38. Berger A, Cavallero S, Dominguez E, et al. Spectral-domain optical coherence  
7 tomography of the rodent eye: highlighting layers of the outer retina using signal  
8 averaging and comparison with histology. *PLoS One.* 2014; 9:e96494.

9  
10 39. Hoerster R, Muether PS, Vierkotten S, et al. In-vivo and ex-vivo characterization  
11 of laser-induced choroidal neovascularization variability in mice. *Graefes Arch*  
12 *Clin Exp Ophthalmol.* 2012; 250:1579-1586.

1 Sulaiman, R.S.

2  
3 **Figure Legends**

4  
5  
6  
7 Figure 1. Determination of ellipsoid axes in Micron OCT images. A) Representative  
8 images showing the horizontal plane of OCT imaging (*red line*) in the bright field fundus  
9 photographs and the radii *a* (width) & *b* (depth relative to the retina) on the  
10 corresponding zoomed in OCT scan. B) Representative images showing the vertical  
11 plane in the bright field image and radius *c* (length) on the corresponding orthogonal  
12 zoomed in OCT scan. C) A schematic diagram showing an ellipsoid with labeled axes  
13 corresponding to the OCT images, and the equation used in calculating ellipsoid  
14 volume. Scale bars = 100  $\mu\text{m}$ . Abbreviations; ganglion cell layer (GCL), outer nuclear  
15 layer (ONL), retinal pigment epithelium (RPE).  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

29  
30  
31 Figure 2. L-CNV lesion volumes calculated from Micron OCT images obtained 14 days  
32 post-laser, analyzed by two independent graders, correlate with those calculated based  
33 on choroidal flatmount Z-stacks. Grader 1 (*left*) Spearman's  $\rho = 0.79$ ,  $P < 0.01$ . Grader 2  
34 (*right*)  $\rho = 0.78$ ,  $P < 0.05$ .  $n = 10$ .  
35  
36  
37  
38  
39  
40  
41

42  
43 Figure 3. Choroidal flatmounts stained with agglutinin show a significant reduction in  
44 CNV lesion volume after anti-VEGF treatment. A) Representative images from confocal  
45 microscopy for CNV lesions from vehicle-treated (*left*) and anti-VEGF-treated eyes  
46 (*right*). Scale bars = 50  $\mu\text{m}$ . B) Quantification of the CNV lesion volume from Z-stack  
47 images using ImageJ software demonstrated a significant reduction in CNV lesion  
48 volume after anti-VEGF intravitreal injection compared to vehicle treated controls,  
49  
50  
51  
52  
53  
54  
55  
56  
57 \*\* $P < 0.01$ , Mann-Whitney test. Mean  $\pm$  SEM,  $n = 6$ .  
58  
59  
60

1 Sulaiman, R.S.  
2  
3  
4

5 Figure 4. Quantification of L-CNV lesions by OCT shows a significant reduction in lesion  
6 volume after anti-VEGF treatment. A) Representative images of L-CNV lesions, shown  
7 between red brackets, from vehicle-treated (*left*) and anti-VEGF-treated eyes (*right*)  
8 obtained after 7 days (*top*) and 14 days (*bottom*). B) Quantification of the CNV lesion  
9 volume calculated as an ellipsoid, showing a significant reduction in CNV lesion volume  
10 after anti-VEGF intravitreal injection compared to vehicle treated controls, after both 7  
11 and 14 days, with  $**P < 0.01$ , Mann-Whitney test. Note different y-axis scales. Mean  $\pm$   
12 SEM, n = 6.  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26

27 Figure 5. L-CNV lesion volumes following treatments calculated from Micron OCT  
28 images correlate with those calculated based on choroidal flatmount Z-stacks. (A) OCT  
29 calculations at 7 days, Spearman's  $\rho = 0.82$ . (B) OCT calculations at 14 days,  $\rho = 0.82$ .  
30 Vehicle-treated, blue, and anti-VEGF-treated eyes, red.  $P < 0.01$ , n = 6 per treatment.  
31 Note different y-axis scales.  
32  
33  
34  
35  
36  
37  
38  
39  
40

41 Figure 6. L-CNV lesion volumes calculated from InVivoVue OCT images obtained 10  
42 days post-laser correlate with those calculated based on choroidal flatmount Z-stacks.  
43 A) Representative images showing the horizontal plane of OCT imaging (*green line*) in  
44 the en face image and the corresponding B-scan focus on the optic nerve head (ONH).  
45 Scale bar = 34  $\mu\text{m}$ . B) Representative images showing the en face image and the  
46 corresponding B-scan at an L-CNV lesion (*arrow*). C) A significant correlation is  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Sulaiman, R.S.

observed between 3D measurements of OCT images and confocal Z-stack images,

Spearman's  $\rho = 0.75$ ,  $P < 0.05$ ,  $n = 10$ .

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Figure 1




Figure 1. Determination of ellipsoid axes in Micron OCT images. A) Representative images showing the horizontal plane of OCT imaging (red line) in the bright field fundus photographs and the radii a (width) & b (depth relative to the retina) on the corresponding zoomed in OCT scan. B) Representative images showing the vertical plane in the bright field image and radius c (length) on the corresponding orthogonal zoomed in OCT scan. C) A schematic diagram showing an ellipsoid with labeled axes corresponding to the OCT images, and the equation used in calculating ellipsoid volume. Scale bars = 100  $\mu$ m. Abbreviations; ganglion cell layer (GCL), outer nuclear layer (ONL), retinal pigment epithelium (RPE).  
254x190mm (300 x 300 DPI)

Figure 2




Figure 2. L-CNV lesion volumes calculated from Micron OCT images obtained 14 days post-laser, analyzed by two independent graders, correlate with those calculated based on choroidal flatmount Z-stacks. Grader 1 (left) Spearman's  $\rho = 0.79$ ,  $P < 0.01$ . Grader 2 (right)  $\rho = 0.78$ ,  $P < 0.05$ .  $n = 10$ . 82x35mm (600 x 600 DPI)

Figure 3




Figure 3. Choroidal flatmounts stained with agglutinin show a significant reduction in CNV lesion volume after anti-VEGF treatment. A) Representative images from confocal microscopy for CNV lesions from vehicle-treated (left) and anti-VEGF-treated eyes (right). Scale bars = 50 µm. B) Quantification of the CNV lesion volume from Z-stack images using ImageJ software demonstrated a significant reduction in CNV lesion volume after anti-VEGF intravitreal injection compared to vehicle treated controls, \*\*P<0.01, Mann-Whitney test. Mean ± SEM, n = 6.  
150x160mm (300 x 300 DPI)






Figure 4. Quantification of L-CNV lesions by OCT shows a significant reduction in lesion volume after anti-VEGF treatment. A) Representative images of L-CNV lesions, shown between red brackets, from vehicle-treated (left) and anti-VEGF-treated eyes (right) obtained after 7 days (top) and 14 days (bottom). B) Quantification of the CNV lesion volume calculated as an ellipsoid, showing a significant reduction in CNV lesion volume after anti-VEGF intravitreal injection compared to vehicle treated controls, after both 7 and 14 days, with  $**P < 0.01$ , Mann-Whitney test. Note different y-axis scales. Mean  $\pm$  SEM, n = 6. 240x146mm (300 x 300 DPI)

Figure 5




Figure 5. L-CNV lesion volumes following treatments calculated from Micron OCT images correlate with those calculated based on choroidal flatmount Z-stacks. (A) OCT calculations at 7 days, Spearman's  $\rho = 0.82$ . (B) OCT calculations at 14 days,  $\rho = 0.82$ . Vehicle-treated, blue, and anti-VEGF-treated eyes, red.  $P < 0.01$ ,  $n = 6$  per treatment. Note different y-axis scales.

225x96mm (300 x 300 DPI)

Figure 6




Figure 6. L-CNV lesion volumes calculated from InVivoVue OCT images obtained 10 days post-laser correlate with those calculated based on choroidal flatmount Z-stacks. A) Representative images showing the horizontal plane of OCT imaging (green line) in the en face image and the corresponding B-scan focus on the optic nerve head (ONH). Scale bar = 34 μm. B) Representative images showing the en face image and the corresponding B-scan at an L-CNV lesion (arrow). C) A significant correlation is observed between 3D measurements of OCT images and confocal Z-stack images, Spearman's  $\rho = 0.75$ ,  $P < 0.05$ ,  $n = 10$ . 254x136mm (300 x 300 DPI)